Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
policlinico.mi.itLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
211
Active
55
Phase 3
9
Total enrollment
150,999
Pipeline matrix
Showing 19 of 19 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Infiltrative treatment with CB-PRP | — | — | — | — | — | 1 | |
| Bulevirtide | — | — | — | — | — | 4 | |
| precision medicine approach | — | — | — | — | — | 1 | |
| Liver resection to isolate cells | — | — | — | — | — | 1 | |
| cytokine essays | — | — | — | — | — | 1 | |
| NGS | — | — | — | — | — | 1 | |
| Fecal microbiome | — | — | — | — | — | 1 | |
| Erythropoietin | — | — | — | — | — | 1 | |
| Luspatercept | — | — | — | — | — | 1 | |
| Thrombopoietin Receptor Agonist | — | — | — | — | — | 1 | |
| G-CSF | — | — | — | — | — | 1 | |
| WES analysis | — | — | — | — | — | 1 | |
| whole-genome methylation analysis | — | — | — | — | — | 1 | |
| Whole exome sequencing - WES | — | — | — | — | — | 1 | |
| Sildenafil Oral Suspension Compared to Orodispersible | — | — | — | — | — | 1 | |
| Influenza vaccination | — | — | — | — | — | 1 | |
| SARS-CoV-2 vaccine | — | — | — | — | — | 1 | |
| Drospirenone 4 mg orally | — | — | — | — | — | 1 | |
| Dienogest 2 mg orally | — | — | — | — | — | 1 |
Next readouts
- 2023-11-01
- 2024-11-24
- 2025-11-30
- 2025-12
- 2026-02
- 2026-06-30
- 2026-07
- 2026-07-31
- 2030-06-30
- 2030-07-31
Top conditions
- Endometriosis12
- Celiac Disease8
- COVID-197
- Acute Respiratory Failure5
- Parkinson Disease5
- Hepatitis D4
- Septic Shock4
- Endometriosis-related Pain4
Frequently asked questions about Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- How many clinical trials does Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico have on ClinicalTrials.gov?
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico is listed as the lead sponsor on 211 clinical trials in ClinicalTrials.gov, 55 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico's trials are in Phase 3?
- 9 of Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico's trials are in Phase 3, spread across 19 active drug programs.
- What therapeutic areas does Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico focus on?
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico's most-studied conditions on ClinicalTrials.gov are Endometriosis, Celiac Disease, COVID-19, Acute Respiratory Failure, Parkinson Disease.
- When are Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico's next clinical trial readouts?
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico has 10 upcoming primary-completion readouts tracked here; the soonest is “Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)”, expected around 2023-11-01.